05296
烟酰胺
pharmaceutical secondary standard; traceable to USP, PhEur and BP
别名:
烟酰胺, 吡啶-3-甲酰胺, 烟碱酰胺, 维生素 B3, 维生素 PP
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C6H6N2O
化学文摘社编号:
分子量:
122.12
EC Number:
202-713-4
UNSPSC Code:
41116000
MDL number:
Beilstein/REAXYS Number:
383619
grade
certified reference material, pharmaceutical secondary standard
agency
traceable to BP 460, traceable to Ph. Eur. N0600000, traceable to USP 1462006
mp
128-131 °C (lit.)
SMILES string
NC(=O)c1cccnc1
InChI
1S/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9)
InChI key
DFPAKSUCGFBDDF-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
烟酰胺是维生素B3的酰胺衍生物，是PARP抑制剂
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2
存储类别
11 - Combustible Solids
flash_point_f
302.0 °F - closed cup
flash_point_c
150 °C - closed cup
法规信息
新产品
此项目有
Ivana Cristina Fernandez et al.
Journal of pediatric endocrinology & metabolism : JPEM, 26(3-4), 347-355 (2013-06-07)
Abstract Objectives: The aim was to evaluate the treatment with acetyl-L-carnitine (50 mg/kg/day) and nicotinamide (25 mg/kg/day) in children at risk of type 1 diabetes. This treatment was effective and harmless in experimental type 1 diabetes in mice. Nine out
Takeshi Natori et al.
Gan to kagaku ryoho. Cancer & chemotherapy, 40(5), 635-637 (2013-07-19)
Sorafenib is an oral multi-kinase inhibitor that targets tumor growth and angiogenesis signal transduction pathways. Two global phase III trials showed that sorafenib prolonged the survival of patients with advanced hepatocellular carcinoma (HCC). Based on the positive results of these
Case of sorafenib-induced thyroid storm.
Sigurdis Haraldsdottir et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(16), e262-e264 (2013-04-24)
Takeshi Ueda et al.
Japanese journal of clinical oncology, 43(6), 616-628 (2013-05-01)
Axitinib is a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2 and 3. The efficacy and safety of axitinib in Japanese patients with metastatic renal cell carcinoma were evaluated. A subgroup analysis was conducted in
Ning Jia et al.
Anticancer research, 33(6), 2797-2800 (2013-06-12)
Post-transplant hepatocellular carcinoma recurrence has been reported to be between 15-18% and is higher among patients with high-risk features (bilobar tumor, macrovascular invasion, or multifocality). There are no known treatments which reduce risk of recurrence post-transplant. Sorafenib is currently approved
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 116416-25G | 04061835521098 |
| 116416-5G | 04061838704320 |
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持